Chimeric nucleic acids encoding polypeptides comprising TNF...

Details Chimeric nucleic acids encoding polypeptides comprising TNF... Chimeric nucleic acids encoding polypeptides comprising TNF...

2011-06-21

2011-06-21

Gambel, Phillip (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S023500, C435S252300, C435S320100, C435S455000

Reexamination Certificate

active

07964712

ABSTRACT:
The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNFα, comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNFα, wherein the encoded domain or subdomain replaces a cleavage site of native TNFα, and a second nucleotide sequence encoding a domain or subdomain of native TNFα that binds to a TNFα receptor. The encoded chimeric TNFα is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNFα receptor on the surface of a cell. The chimeric TNFα is therefore useful in methods for inducing apoptosis of a cell expressing a TNFα receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNFα that is expressed on the surface of the cell.

REFERENCES:
patent: 4990455 (1991-02-01), Yamagishi et al.
patent: 5422104 (1995-06-01), Fiers et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5486463 (1996-01-01), Lesslauer et al.
patent: 5519119 (1996-05-01), Yamada et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5565321 (1996-10-01), Spriggs et al.
patent: 5573924 (1996-11-01), Beckmann et al.
patent: 5606023 (1997-02-01), Chen et al.
patent: 5716805 (1998-02-01), Srinivasan et al.
patent: 5817516 (1998-10-01), Kehry et al.
patent: 5861310 (1999-01-01), Freeman et al.
patent: 5962406 (1999-10-01), Armitage et al.
patent: 6017527 (2000-01-01), Maraskovsky et al.
patent: 6106832 (2000-08-01), Spriggs et al.
patent: 6451759 (2002-09-01), Kang et al.
patent: 6544523 (2003-04-01), Chu
patent: 7070771 (2006-07-01), Kipps et al.
patent: 7495090 (2009-02-01), Prussak et al.
patent: 7524944 (2009-04-01), Kipps et al.
patent: 7786282 (2010-08-01), Prussak et al.
patent: 2002/0022017 (2002-02-01), Yu
patent: 2004/0209295 (2004-10-01), Schwabe et al.
patent: 2005/0158831 (2005-07-01), Kornbluth
patent: 0317641 (1989-05-01), None
patent: 0585943 (1993-03-01), None
patent: 0675200 (1995-10-01), None
patent: 1016721 (2000-07-01), None
patent: WO 91/02540 (1991-03-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 93/19777 (1993-10-01), None
patent: WO 93/24135 (1993-12-01), None
patent: WO 94/04570 (1994-03-01), None
patent: WO 94/04680 (1994-03-01), None
patent: WO 94/17196 (1994-08-01), None
patent: WO 95/14487 (1995-06-01), None
patent: WO 95/17202 (1995-06-01), None
patent: WO 95/18819 (1995-07-01), None
patent: WO 95/32627 (1995-12-01), None
patent: WO 96/03141 (1996-02-01), None
patent: WO 96/14876 (1996-05-01), None
patent: WO 96/18413 (1996-06-01), None
patent: WO 96/22370 (1996-07-01), None
patent: WO 98/21232 (1998-05-01), None
patent: WO 98/26061 (1998-06-01), None
Addison et al., “Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model,” Proc. Natl. Acad. Sci. U.S.A., 92:8522-8526 (1995).
Alderson et al., “CD40 expression by human monocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40.” J. Exp. Med. 178: 669-674 (1993).
Ali et al., “PCR-Ligation-PCR Mutagenesis: A Protocol for Creating Gene Fusions and Mutations”, BioTechniques, 18:746-750 (1995).
Ali et al., “The use of DNA viruses as vectors for gene therapy”, Gene Therapy, 1:367-384(1994).
Armitage et al., “CD40 ligand is a T cell growth factor.” Eur. J. Immunol., 23:2326-2331, 1993.
Armitage et al., “Molecular and biological characterization of a murine ligand for CD40”, Nature, 357:80-82 (1992).
Aruffo et al., “The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-Igfvl syndrome.” Cell, 72:291-300,1993.
Attwood, “The Babel of Bioinformatics,” Science 290:471-473 (2000).
Banchereau et al., “Long-Term Human B Cell Lines Dependent on Interleukin-4 and Antibody to CD40,” Science, 251:70-72 (1991).
Banchereau et al., “The CD40 antigen and its ligand.” Annual Review Immunol., 12:881-922,1994.
Berman et al., “Gene transfer in lymphoid cells: Expression of the Thy-1,2 antigen by Thy-1.1 BW5147 lymphoma cells transfected with unfractionated cellular DNA”, Proc. Natl. Acad. Sci. USA, 81:7176-7179 (1984).
Blieden et al., “Class-I MHC Expression in the Mouse Lung Carcinoma, Line 1: A Model for Class-I Inducible Tumors”, Int. J. Cancer Supp., 6:82-89 (1991).
Boles et al., “A rapid and highly efficient method for PCR-based site-directed mutagenesis using only one new primer”, Curr. Genet, 28:197-198 (1995).
Boris-Lawrie et al., “Recent advances in retrovirus vector technology”, Current Opinion in Genetics and Development, 3:102-109 (1993).
Brody et al., “Adenovirus-mediated in Vivo Gene Transfer”, Ann. N. Y. Acad. Sci., 716:90-103 (1994).
Cadwell et al., “Randomization of Genes by PCR Mutagenesis”, PCR Methods and Applications, 2:28-33 (1992).
Cantwell et al., “Acquired CD40-ligand deficiency in chronic lymphocytic leukemia”, Nature Medicine, 3:984-989 (1997).
Cantwell et al., “Adenovirus Vector Infection of Chronic Lymphocytic Leukemia B Cells”, Blood, 88:4676-4683 (1996).
Cantwell et al., “CD95 and FAS-ligand expression and apoptosis in rheumatoid arthritis.” Arthritis and Rheumatism, 39(9), suppl., p. 287 (1996).
Carter, Barrie J., “Adeno-associated virus vectors”, Current Opinion in Biotechnology, 3:533-539(1992).
Castle et al., “Regulation of expression of the ligand for CD40 on T helper lymphocytes.” J. Immunol., 151:1777-1788, 1993.
Clark et al., “Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50”, Proc. Natl. Acad. Sci. U.S.A., 83:4494-4498(1986).
Cooper, Mark J., “Noninfectious Gene Transfer and Expression Systems for Cancer Gene Therapy”, Seminars in Oncology, 23:172-187 (1996).
Cosman et al., “Cloning, sequence and expression of human interleukin-2 receptor”, Nature, 312:768-771 (1984).
Danko et al., “Direct gene transfer into muscle”, Vaccine, 12:1499-1502 (1994).
Davis et al., “Direct Gene Transfer into Skeletal Muscle in Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression”, Human Gene Therapy, 4:151-159(1993).
Deans et al., “Expression of an immunoglobulin heavy chain gene transfected into lymphocytes”, Proc. Natl. Acad. Sci. USA, 81:1292-1296 (1984).
DeMatteo et al., “Gene Transfer to the Thymus”, Annals of Surgery, 222:229-242(1995).
Dilloo, Dagmaretal., “CD40 Ligand Induces an Antileukemia Immune Response in Vivo”, Blood, 90:1927-1933 (1997).
Evans et al., “Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-Arthritic Cytokine Gene to Human Joints with Rheumatoid Arthritis”, Human Gene Therapy, 7:1261-1280 (1996).
Fanslow et al., “Structural characteristics of CD40 ligand that determine biological function”, Seminars in Immunology, 6:267-278 (1994).
Feigner et al., “Improved Cationic Lipid Formulations for in Vivo Gene Therapy”, Ann. N. Y. Acad. Sci., 772:126-139 (1995).
Fisher et al., “In vivo and ex vivo gene transfer to the brain”, Current Opinion in Neurobiology, 4:735-741 (1994).
Flotte et al., “Adeno-associated virus vectors for gene therapy”, Gene Therapy, 2:357-362(1995).
Furth et al., “Gene Transfer into Mammalian Cells by Jet Injection”, Hybridoma, 14:149-152(1995).
Galle et al., “Involvement of the CD95 (APO-1/Fas) Receptor and Ligand in Liver Damage”, J. Exp. Med., 182:1223-1230 (1995).
Glorioso et al., “Development and application of herpes simplex

Affiliated with

Also associated with

Rating

Chimeric nucleic acids encoding polypeptides comprising TNF... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric nucleic acids encoding polypeptides comprising TNF..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric nucleic acids encoding polypeptides comprising TNF... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2733289